Molecular profiles in foregut oncology

Cancer Genetics - Tập 209 - Trang 537-553 - 2016
Prashant Sukharamwala1, Daniel Hennessey1, Thomas Wood1, Shelly Singh1, Carrie Ryan1, Alexander Rosemurgy1
1Florida Hospital Tampa, 3000 Medical Park Drive Suite 310, Tampa, FL 33613, USA

Tài liệu tham khảo

Centers for Disease Control and Prevention National Center for Health Statistics

Winchester, 2006

DeVita, 2008, A history of cancer chemotherapy, Cancer Res, 68, 8643, 10.1158/0008-5472.CAN-07-6611

Gooz, 2010, ADAM-17: the enzyme that does it all, Crit Rev Biochem Mol Biol, 45, 146, 10.3109/10409231003628015

Andren-Sandberg, 2012, Molecular biology of gallbladder cancer: potential clinical implications, N Am J Med Sci, 4, 435, 10.4103/1947-2714.101979

Hong, 2013, ABL regulation by AXL promotes cisplatin resistance in esophageal cancer, Cancer Res, 73, 331, 10.1158/0008-5472.CAN-12-3151

Thomadaki, 2006, BCL2 family of apoptosis-related genes: functions and clinical implications in cancer, Crit Rev Clin Lab Sci, 43, 1, 10.1080/10408360500295626

Vane, 1998, Cyclooxygenases 1 and 2, Annu Rev Pharmacol Toxicol, 38, 97, 10.1146/annurev.pharmtox.38.1.97

Pignochino, 2010, Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas, BMC Cancer, 10, 631, 10.1186/1471-2407-10-631

Valsecchi, 2012, Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?, BMC Cancer, 12, 104, 10.1186/1471-2407-12-104

Farrell, 2009, Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer, Gastroenterology, 136, 187, 10.1053/j.gastro.2008.09.067

Kawada, 2012, Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including gemcitabine, J Hepatobiliary Pancreat Sci, 19, 717, 10.1007/s00534-012-0514-x

Marechal, 2009, Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma, Clin Cancer Res, 15, 2913, 10.1158/1078-0432.CCR-08-2080

Yoon, 2012, Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas, Clin Cancer Res, 18, 546, 10.1158/1078-0432.CCR-11-2272

Hu, 2011, HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma, Mod Pathol, 24, 899, 10.1038/modpathol.2011.47

Arvat, 2000, Insulin-like growth factor I, Drugs Aging, 16, 29, 10.2165/00002512-200016010-00003

Ihle, 2012, Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome, J Natl Cancer Inst, 104, 228, 10.1093/jnci/djr523

Argani, 2001, Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE), Clin Cancer Res, 7, 3862

Zhang, 2006, NF-κB, inflammation and pancreatic carcinogenesis: NF-κB as a chemoprevention target (Review), Int J Oncol, 29, 185

Tanaka, 1997, Multiple types of aberrations in the p16 (INK4a) and the p15(INK4b) genes in 30 esophageal squamous-cell-carcinoma cell lines, Int J Cancer, 70, 437, 10.1002/(SICI)1097-0215(19970207)70:4<437::AID-IJC11>3.0.CO;2-C

Xing, 1999, Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human esophageal squamous cell carcinoma, Clin Cancer Res, 5, 2704

Alsheyab, 2007, Expression of p21 and p27 in gallbladder cancer, Saudi Med J, 28, 683

Vogelstein, 2010, p53: the most frequently altered gene in human cancers, Nat Educ, 3, 6

Chang, 2007, Significance of PML and p53 protein as molecular prognostic markers of gallbladder carcinomas, Pathol Oncol Res, 13, 326, 10.1007/BF02940312

Guo, 2011, Hepatitis C virus core upregulates the methylation status of the RASSF1A promoter through regulation of SMYD3 in hilar cholangiocarcinoma cells, Acta Biochim Biophys Sin (Shanghai), 43, 354, 10.1093/abbs/gmr021

Srivastava, 2013, Cyclin D1, retinoblastoma and p16 protein expression in carcinoma of the gallbladder, Asian Pac J Cancer Prev, 14, 2711, 10.7314/APJCP.2013.14.5.2711

Nakahira, 2007, Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer, Int J Cancer, 120, 1355, 10.1002/ijc.22390

Costello, 2009

Wilentz, 2000, Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression, Cancer Res, 60, 2002

Infante, 2007, Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma, J Clin Oncol, 25, 319, 10.1200/JCO.2006.07.8824

Geng, 2013, TGF-Beta suppresses VEGFA-mediated angiogenesis in colon cancer metastasis, PLoS ONE, 8, 1, 10.1371/journal.pone.0059918

Shi, 2004, Expression of tumor necrosis factor and its receptor in gallstone and gallbladder carcinoma tissue, Hepatobiliary Pancreat Dis Int, 3, 448

Kostopoulos, 2009, Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy, BMC Cancer, 9, 339, 10.1186/1471-2407-9-339

Hu, 2003, Thymidylate synthase expression predicts the response to 5-Fluorouracil-based adjuvant therapy in pancreatic cancer, Clin Cancer Res, 9, 4165

Ferrara, 2005, VEGF as a therapeutic target in cancer, Oncology, 69, 11, 10.1159/000088479

Jazii, 2012

Campbell, 2010, Neoadjuvant treatment of esophageal cancer, World J Gastroenterol, 16, 3793, 10.3748/wjg.v16.i30.3793

Rahma, 2012, Locally advanced cancer of the esophagus, current treatment strategies, and future directions, Front Oncol, 2, 1, 10.3389/fonc.2012.00052

Dragovich, 2006, Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127, J Clin Oncol, 24, 4922, 10.1200/JCO.2006.07.1316

McManus, 2004, Biomarkers of esophageal adenocarcinoma and Barrett's esophagus, Cancer Res, 64, 1561, 10.1158/0008-5472.CAN-03-2438

Scotiniotis, 2001, Accuracy of EUS in the evaluation of Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma, Gastrointest Endosc, 54, 689, 10.1067/mge.2001.119216

Lam, 2000, Molecular biology of esophageal squamous cell carcinoma, Crit Rev Oncol Hematol, 33, 71, 10.1016/S1040-8428(99)00054-2

Kwak, 2006, Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas, Clin Cancer Res, 12, 4283, 10.1158/1078-0432.CCR-06-0189

Wiedmann, 2013, New and emerging combination therapies for esophageal cancer, Cancer Manag Res, 5, 133, 10.2147/CMAR.S32199

Kim, 2013, Molecular targeted therapy for advanced gastric cancer, Korean J Intern Med, 28, 149, 10.3904/kjim.2013.28.2.149

Meza-Junco, 2012, Metastatic gastric cancer—focus on targeted therapies, Biologics, 6, 137

Power, 2009, Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers, Ther Adv Med Oncol, 1, 145, 10.1177/1758834009347323

Prins, 2012, Cyclooxygenase isoenzyme-2 and vascular endothelial growth factor are associated with poor prognosis in esophageal adenocarcinoma, J Gastrointest Surg, 16, 956, 10.1007/s11605-011-1814-1

Yoon, 2011, VEGF as a predictor for response to definitive chemoradiotherapy and COX-2 as a prognosticator for survival in esophageal squamous cell carcinoma, J Korean Med Sci, 26, 513, 10.3346/jkms.2011.26.4.513

Gibson, 2003, Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy, Clin Cancer Res, 9, 6461

Liggett, 1998, Role of the p16 tumor suppressor gene in cancer, J Clin Oncol, 16, 1197, 10.1200/JCO.1998.16.3.1197

Bani-Hani, 2000, Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma, J Natl Cancer Inst, 92, 1316, 10.1093/jnci/92.16.1316

Huang, 2010, Relationship between COX-2 and cell cycle-regulatory proteins in patients with esophageal squamous cell carcinoma, World J Gastroenterol, 16, 5975

Nie, 2002, Detection of multiple gene hypermethylation in the development of esophageal squamous cell carcinoma, Carcinogenesis, 23, 1713, 10.1093/carcin/23.10.1713

Kuwano, 2005, Genetic alterations in esophageal cancer, Surg Today, 35, 7, 10.1007/s00595-004-2885-3

Kwon, 2014, Cetuximab inhibits cisplatin-induced activation of EGFR signaling in esophageal squamous cell carcinoma, Oncol Rep, 32, 1188, 10.3892/or.2014.3302

Zhai, 2013, Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study, Dis Esophagus, 26, 503, 10.1111/j.1442-2050.2012.01380.x

Nemoto, 2001, Overexpression of fatty acid synthase in oesophageal squamous cell dysplasia and carcinoma, Pathobiology, 69, 297, 10.1159/000064636

Zhu, 2011, Inhibition of hypoxia inducible factor 1α expression suppresses the progression of esophageal squamous cell carcinoma, Cancer Biol Ther, 11, 981, 10.4161/cbt.11.11.15707

Duffy, 2014, Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update, Int J Cancer, 134, 2513, 10.1002/ijc.28384

Correa, 2010, Pathology of gastric intestinal metaplasia: clinical implications, Am J Gastroenterol, 105, 493, 10.1038/ajg.2009.728

Novelli, 2010, DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours, Histopathology, 57, 259, 10.1111/j.1365-2559.2010.03624.x

Durães, 2014, Biomarkers for gastric cancer: prognostic, predictive or targets of therapy?, Virchows Arch, 464, 367, 10.1007/s00428-013-1533-y

Sherman, 2013, Treatment trends and predictors of adjuvant and neoadjuvant therapy for gastric adenocarcinoma in the United States, Ann Surg Oncol, 20, 362, 10.1245/s10434-012-2552-7

Cunningham, 2006, Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer, N Engl J Med, 355, 11, 10.1056/NEJMoa055531

Galsky, 2012, Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors, Invest New Drugs, 30, 695, 10.1007/s10637-010-9541-0

Lieto, 2008, Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients, Ann Surg Oncol, 15, 69, 10.1245/s10434-007-9596-0

Ohtsu, 2011, Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo controlled phase III study, J Clin Oncol, 29, 3968, 10.1200/JCO.2011.36.2236

Fuchs, 2014, Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial, Lancet, 383, 31, 10.1016/S0140-6736(13)61719-5

DeMatteo, 2007, Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor, Ann Surg, 245, 347, 10.1097/01.sla.0000236630.93587.59

Songdej, 2014, GIST treatment options after tyrosine kinase inhibitors, Curr Treat Options Oncol, 15, 493, 10.1007/s11864-014-0295-3

Bauer, 2007, KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway, Oncogene, 26, 7560, 10.1038/sj.onc.1210558

Shin, 2013, Molecular targeted therapy for hepatocellular carcinoma: current and future, World J Gastroenterol, 19, 6144, 10.3748/wjg.v19.i37.6144

Marrero, 2009, Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma, Gastroenterology, 137, 110, 10.1053/j.gastro.2009.04.005

Durazo, 2008, Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma, J Gastroenterol Hepatol, 23, 1541, 10.1111/j.1440-1746.2008.05395.x

Miura, 1997, Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma, J Hepatol, 27, 854, 10.1016/S0168-8278(97)80323-6

Poon, 2004, Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma, Br J Surg, 91, 1354, 10.1002/bjs.4594

Schoenleber, 2009, Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis, Br J Cancer, 100, 1385, 10.1038/sj.bjc.6605017

Llovet, 2008, Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 378, 10.1056/NEJMoa0708857

Cheng, 2009, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial, Lancet Oncol, 10, 25, 10.1016/S1470-2045(08)70285-7

Hisaka, 1999, Expressions of epidermal growth factor family and its receptor in hepatocellular carcinoma cell lines: relationship to cell proliferation, Int J Oncol, 14, 453

Zhu, 2011, Phase 1/2 study of everolimus in advanced hepatocellular carcinoma, Cancer, 117, 5094, 10.1002/cncr.26165

Puhalla, 2004, p53 Analysis in gallbladder cancer: comparison of gene analysis versus immunohistochemistry, Anticancer Res, 24, 1201

Riener, 2010, Cell adhesion molecules P-cadherin and CD24 are markers for carcinoma and dysplasia in the biliary tract, Hum Pathol, 41, 1558, 10.1016/j.humpath.2009.12.016

Liu, 2011, Clinicopathologic and prognostic significance of CD24 in gallbladder carcinoma, Pathol Oncol Res, 17, 45, 10.1007/s12253-010-9278-2

Kalekou, 2011, Cytokeratin 7 and 20 expression in gallbladder carcinoma, Pol J Pathol, 1, 25

Chang, 2004, Phenotypic alterations of mucins and cytokeratins during gallbladder carcinogenesis, Pathol Int, 54, 576, 10.1111/j.1440-1827.2004.01666.x

Wu, 2005, Expression of homeodomain protein CDX2 in gallbladder carcinomas, J Cancer Res Clin Oncol, 131, 271, 10.1007/s00432-004-0658-4

Chang, 2007, Expression of the caudal-type homeodomain transcription factor CDX2 is related to clinical outcome in biliary tract carcinoma, J Gastroenterol Hepatol, 22, 389, 10.1111/j.1440-1746.2006.04487.x

Saad, 2011, CDX2 as a marker for intestinal differentiation: its utility and limitations, World J Gastrointest Surg, 3, 159, 10.4240/wjgs.v3.i11.159

Weigt, 2010, Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer, Expert Rev Gastroenterol Hepatol, 4, 395, 10.1586/egh.10.45

Goodsell, 2006, The molecular perspective: cisplatin, Oncologist, 11, 316, 10.1634/theoncologist.11-3-316

Malka, 2009, A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: interim analysis of the BINGO trial, J Clin Oncol, 27, 10.1200/jco.2009.27.15_suppl.4520

Mini, 2006, Cellular pharmacology of gemcitabine, Ann Oncol, 17, v7, 10.1093/annonc/mdj941

O'Dell, 2012, Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma, Cancer Res, 72, 1557, 10.1158/0008-5472.CAN-11-3596

Tada, 1992, High incidence of ras gene mutation in intrahepatic cholangiocarcinoma, Cancer, 69, 1115, 10.1002/cncr.2820690509

Levi, 1991, Multiple K-ras codon 12 mutations in cholangiocarcinoma demonstrated with sensitive polymerase chain reaction techniques, Cancer Res, 51, 3497

Shimonishi, 2002, Increasing expression of gastrointestinal phenotypes and p53 along with histologic progression of intraductal papillary neoplasia of the liver, Hum Pathol, 33, 503, 10.1053/hupa.2002.124030

Lubner, 2010, Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study, J Clin Oncol, 28, 3491, 10.1200/JCO.2010.28.4075

Kang, 1999, Mutation of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma, Lab Invest, 79, 477

Philip, 2006, Phase II study of erlotinib in patients with advanced biliary cancer, J Clin Oncol, 24, 3069, 10.1200/JCO.2005.05.3579

Lee, 2012, Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study, Lancet Oncol, 13, 181, 10.1016/S1470-2045(11)70301-1

Furuse, 2011, Targeted therapy for biliary tract cancer, Cancers (Basel), 3, 2243, 10.3390/cancers3022243

Ramanathan, 2009, A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer, Cancer Chemother Pharmacol, 64, 777, 10.1007/s00280-009-0927-7

Gruenberger, 2010, Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study, Lancet Oncol, 11, 1142, 10.1016/S1470-2045(10)70247-3

Malka, 2014, Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial, Lancet Oncol, 14, 70212

Bengala, 2010, Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial, J Cancer, 102, 68, 10.1038/sj.bjc.6605458

Zhu, 2010, Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study, Lancet Oncol, 11, 48, 10.1016/S1470-2045(09)70333-X

El-Khoueiry, 2007, A phase II study of sorafenib (BAY 43-9006) as single agent in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinomas, J Clin Oncol, 25, 10.1200/jco.2007.25.18_suppl.4639

Bernini, 2001, A new human chromogranin “A” immunoradiometric assay for the diagnosis of neuroendocrine tumours, Br J Cancer, 84, 636, 10.1054/bjoc.2000.1659

Salla, 2009, CK19 and CD10 expression in pancreatic neuroendocrine tumors diagnosed by endoscopic ultrasound-guided fine-needle aspiration cytology, Cancer Cytopathol, 117, 516

Schmitt, 2007, WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors, Am J Surg Pathol, 31, 1677, 10.1097/PAS.0b013e31805f675d

Raymond, 2011, Sunitinib malate for the treatment of pancreatic neuroendocrine tumors, N Engl J Med, 364, 501, 10.1056/NEJMoa1003825

Hobday, 2007, MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a Phase II Consortium (P2C) study, J Clin Oncol, 25, 4504, 10.1200/jco.2007.25.18_suppl.4504

Grande, 2013, sVEGFR2 and circulating tumor cells to predict for the efficacy of pazopanib in neuroendocrine tumors (NETs): PAZONET subgroup analysis, J Clin Oncol, 31, 10.1200/jco.2013.31.15_suppl.4140

Zitzmann, 2007, The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells, Neuroendocrinology, 85, 54, 10.1159/000100057

Yao, 2011, Everolimus for advanced pancreatic neuroendocrine tumors, N Engl J Med, 364, 514, 10.1056/NEJMoa1009290

Gullo, 1994, Diabetes and the risk of pancreatic cancer, N Engl J Med, 331, 81, 10.1056/NEJM199407143310203

Pannala, 2009, New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer, Lancet Oncol, 10, 88, 10.1016/S1470-2045(08)70337-1

Boeck, 2013, EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104, Br J Cancer, 108, 469, 10.1038/bjc.2012.495

Apple, 1999, Immunohistochemical evaluation of K-ras, p53, and HER-2/neu expression in hyperplastic, dysplastic, and carcinomatous lesions of the pancreas: evidence for multistep carcinogenesis, Hum Pathol, 30, 123, 10.1016/S0046-8177(99)90265-4

Tsiambas, 2006, HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis, JOP, 7, 283

Koeppen, 2001, Overexpression of HER2/neu in solid tumours: an immunohistochemical survey, Histopathology, 38, 96, 10.1046/j.1365-2559.2001.01084.x

Von Hoff, 2011, Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial, J Clin Oncol, 29, 4548, 10.1200/JCO.2011.36.5742

Frese, 2012, nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer, Cancer Discov, 2, 260, 10.1158/2159-8290.CD-11-0242

Von Hoff, 2013, Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine, N Engl J Med, 369, 1691, 10.1056/NEJMoa1304369

Winter, 2012, A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers, PLoS ONE, 7, e40157, 10.1371/journal.pone.0040157

Shimizu, 2012, Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma, Cancer Sci, 103, 739, 10.1111/j.1349-7006.2012.02214.x

Chen, 2013, Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation, Sci Rep, 3, 1870, 10.1038/srep01870

Miyaki, 2003, Role of Smad4 (DPC4) inactivation in human cancer, Biochem Biophys Res Commun, 306, 799, 10.1016/S0006-291X(03)01066-0

Kubota, 2003, Usefulness of endoscopic biopsy using immunostaining of p53 and Ki-67 in tumors of the ampulla of Vater, Pathol Int, 53, 361, 10.1046/j.1440-1827.2003.01482.x

Kloppel, 2009, Pathology of exocrine pancreatic tumors, 601

Chu, 2005, Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2, Am J Surg Pathol, 29, 359, 10.1097/01.pas.0000149708.12335.6a

Matsubayashi, 1999, Differences in mucus and K-ras mutation in relation to phenotypes of tumors of the papilla of Vater, Cancer, 86, 596, 10.1002/(SICI)1097-0142(19990815)86:4<596::AID-CNCR8>3.0.CO;2-H

Zhou, 2004, Carcinoma of the ampulla of Vater: comparative histologic/immunohistochemical classification and follow-up, Am J Surg Pathol, 28, 875, 10.1097/00000478-200407000-00005

Ajiki, 2001, Proliferating cell nuclear antigen, p53, and c-erbB-2 expression in relation to clinicopathological variables and prognosis in cancer of the ampulla of Vater, Hepatogastroenterology, 48, 1266

Vaidya, 1996, Combined analysis of expression of e-erbB-2, Ki67 antigen, and tenascin provides a better prognostic indicator of carcinomas of the papilla of Vater, Pancreas, 12, 196, 10.1097/00006676-199603000-00015

Zhu, 1996, Adenocarcinoma of duodenum and ampulla of Vater: clinicopathology study and expression of p53, c-neu, TGF-alpha, CEA, and EMA, J Surg Oncol, 61, 100, 10.1002/(SICI)1096-9098(199602)61:2<100::AID-JSO3>3.0.CO;2-G

Moore, 2007, Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group, J Clin Oncol, 25, 1960, 10.1200/JCO.2006.07.9525

Walsh, 2013, EGFR and HER2 inhibition in pancreatic cancer, Invest New Drugs, 31, 558, 10.1007/s10637-012-9891-x

Walters, 2013, Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib, Neoplasia, 15, 143, 10.1593/neo.121712

Wang, 2012, Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction, World J Surg Oncol, 10, 14, 10.1186/1477-7819-10-14

Pimiento, 2015, Annexin A8 is a prognostic marker and potential therapeutic target for pancreatic cancer, Pancreas, 44, 122, 10.1097/MPA.0000000000000218

Thông tin
Thông tin xuất bản

Cancer Genetics

Tập 209

537-553

Thông tin tác giả